Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712823 · ClinicalTrials.gov registry record · Phase 2
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
A Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, sponsored by Crinetics Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 9
- Study locations
NCT06712823 is a Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia that is actively recruiting participants, run by Crinetics Pharmaceuticals. The registered enrollment target is 150 participants, above the 84-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (79% higher). The trial reports 9 study locations across 6 states.
The verdict
NCT06712823, a Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, is actively recruiting participants, sponsored by Crinetics Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).
Conditions Studied
Interventions
- DRUG atumelnant (CRN04894)
Study Locations (9)
Other
- Crinetics Study Site - São Paulo
- Crinetics Study Site - Roma
- Crinetics Study Site - Birmingham
- Crinetics Study Site - London
Minnesota
- Crinetics Study Site, Minneapolis, Minnesota 55454 - Minneapolis
North Carolina
- Crinetics Study Site - Morehead City
Córdoba Province
- Crinetics Study Site - Córdoba
São Paulo
- Crinetics Study Site - Botucatu
Bavaria
- Crinetics Study Site - Munich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06712823
The ClinicalTrials.gov registry entry for NCT06712823 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 84-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (79% higher). The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which atumelnant (CRN04894) is the first listed.
NCT06712823 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Other, Minnesota, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06712823 about?
NCT06712823 is a clinical study titled "An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894". The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).
What is the current status of trial NCT06712823?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-02-25. Estimated completion is 2027-11.
What conditions does trial NCT06712823 study?
This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia.
What interventions are being tested in trial NCT06712823?
The interventions under investigation include: atumelnant (CRN04894) (DRUG).
Who is sponsoring clinical trial NCT06712823?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712823 being conducted?
This trial has 9 study locations across Minnesota, North Carolina, Córdoba Province, São Paulo, Bavaria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Adrenal Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
RECRUITING · Phase 2
-
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
COMPLETED · Phase 2
-
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
RECRUITING · Phase 1
-
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
RECRUITING · Phase 3
-
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
ACTIVE NOT RECRUITING · Phase 1
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Congenital Adrenal Hyperplasia
All registered trials for this condition
Classic Congenital Adrenal Hyperplasia
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.